Angiotensin Receptor Agonist

AVE 0991 is a nonpeptide and orally active angiotensin-(1-7) receptor agonist with an IC₅₀ of 21 nM.

Angiotensin II 5-valine is an agonist of angiotensin receptor.

Aclerastide (DSC-127) is an angiotensin receptor agonist. Aclerastide also is a peptide analog of angiotensin II. Aclerastide can be used for the research of tissue regeneration in diabetic ulcers.

Angiotensin II (3-8), human (TFA) is a less effective agonist at the angiotensin AT₁ receptor.

L-162313 is a non-peptide angiotensin II AT1 and AT2 receptor agonist, with IC₅₀ values of 1.1 and 2.0 nM for AT1 and AT2 receptor, respectively. L-162313 can be used for the research of vasoconstriction, aldosterone release, and cardiovascular growth.

AVE 0991 sodium salt is a nonpeptide and orally active Ang-(1-7) receptor Mas agonist. AVE 0991 competes for high-affinity binding of [¹²⁵I]-Ang-(1-7) to bovine aortic endothelial cell membranes with IC₅₀ of 21 nM.

Sar-Arg-Val-Tyr-Val-His-NH2 is a G_q-biased agonists, exhibits 10-fold larger molecular efficacies at the AT₁R-Gq fusion protein compared with the AT₁R-βarr2 fusion protein.

Angiotensin II (1-4), human (TFA) is an endogenous peptide produced from AT I by angiotensin-converting-enzyme (ACE). Angiotensin II binds the AT II type 1 (AT1) receptor, stimulating GPCRs in vascular smooth muscle cells and increasing intracellular Ca²⁺ levels. Angiotensin II also acts at the Na⁺/H⁺ exchanger in the proximal tubules of the kidney.

Angiotensin II (1-4), human is an endogenous peptide produced from AT I by angiotensin-converting-enzyme (ACE). Angiotensin II binds the AT II type 1 (AT1) receptor, stimulating GPCRs in vascular smooth muscle cells and increasing intracellular Ca²⁺ levels. Angiotensin II also acts at the Na⁺/H⁺ exchanger in the proximal tubules of the kidney.

Angiotensin II (3-8), human is a less effective agonist at the angiotensin AT₁ receptor.

Buloxibutid (AT2 receptor agonist C21) (Standard) is the analytical standard of Buloxibutid (HY-100113). This product is intended for research and analytical applications. Buloxibutid is an orally active, selective angiotensin II type 2 receptor (AT2R) agonist, with a K_i value of 0.4 nM for porcine AT2R. Buloxibutid exerts effects such as vasodilation, anti-inflammation, anti-fibrosis (promoting the expression of collagenase MMP-13) and tissue repair mainly by activating the NO/cGMP pathway, inhibiting the pro-proliferative MAPK signaling, and suppressing the pro-fibrotic TGF-β/Smad pathway as well as the inflammatory NF-κB pathway. Buloxibutid can be used in research related to idiopathic pulmonary fibrosis, hypertension, and systemic sclerosis.